<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933669</url>
  </required_header>
  <id_info>
    <org_study_id>IIT20210023C-R1</org_study_id>
    <nct_id>NCT04933669</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors</brief_title>
  <acronym>ZJGIST-01</acronym>
  <official_title>Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Hospital of Zhejiang Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo No. 1 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was&#xD;
      relatively low, and the relapse-free survival rate was relatively low, which needed to be&#xD;
      further improved. A few retrospective analyses and a small sample of prospective studies have&#xD;
      found that neoadjuvant therapy with imatinib mesylate can improve R0 resection rates. Whether&#xD;
      neoadjuvant therapy prolongs long-term survival remains unclear. The primary objective of&#xD;
      this study was to evaluate 5-year progression-free survival (PFS) for GIST patients with high&#xD;
      recurrence risk after neoadjuvant treatment with imatinib mesylate.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2029</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival（PFS）</measure>
    <time_frame>5 years</time_frame>
    <description>Progression free survival（PFS）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival（OS）</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival（OS）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate （ORR）</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Rate of complete and partial response according to Choi criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>complete resection rate with microscopically negative margin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Progression-free Survival</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Neoadjuvant</condition>
  <arm_group>
    <arm_group_label>Imatinib neoadjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral imatinib mesylate 400mg once daily for 3-12 months in the absence of disease progression or unacceptable toxicity. Within 1 week after completion of preoperative imatinib mesylate, patients with responding or stable disease undergo surgical resection. After complete resection, patients receive oral imatinib mesylate 400mg once daily for 36 months in the absence of disease progression or unacceptable toxicity, and are followed for 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib</intervention_name>
    <description>Imatinib neoadjuvant therapy</description>
    <arm_group_label>Imatinib neoadjuvant</arm_group_label>
    <other_name>neoadjuvant therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Preoperative histologically confirmed primary gastrointestinal stromal tumor&#xD;
&#xD;
          -  Tumor must stain positive for c-Kit (CD117) and/or discovered on gist-1 (DOG-1) by&#xD;
             immunohistochemistry&#xD;
&#xD;
          -  Gene mutation test report including c-kit exons 9,11,13 and 17 and platelet-derived&#xD;
             growth factor receptor alpha (PDGFRA) exons 12 and 18&#xD;
&#xD;
          -  High risk GIST (as modified National Institutes of Health (NIH) 2008): stomach&#xD;
             (maximum tumor diameter&gt; 10.0cm), nonstomach (maximum tumor diameter&gt; 5.0cm)&#xD;
&#xD;
          -  Gender is not limited. Age: ≥ 18 years and ≤ 80 years old&#xD;
&#xD;
          -  Performance status: Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
          -  Patient had informed consent and signed a written consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Asp842Val (D842V) mutation in Exon 18 of PDGFRA gene, or wild type (c-kit exon&#xD;
             9,11,13,17, and PDGFRA Exon 12,18), or c-kit exon 9 mutation&#xD;
&#xD;
          -  Treated with tyrosine kinase inhibitors including Imatinib&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and/or Alanine aminotransferase (ALT)&gt;2.5×ULN(upper&#xD;
             limit of normal)，or Total bilirubin (TBIL)&gt;1.5×ULN，or Creatinine (Cr)&gt;1.0×ULN&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1.5 × 10 ^ 9 / L；or Platelet count (PLT) &lt; 75 × 10 ^&#xD;
             9 / L；or Hemoglobin (Hb) ≥ 90 g / L&#xD;
&#xD;
          -  Previous or concurrent other active malignant tumors (except for basal cell carcinoma&#xD;
             of the skin, or cervical cancer in situ that has undergone curative therapy)&#xD;
&#xD;
          -  Distant metastases are present&#xD;
&#xD;
          -  Any of the following conditions during the 12 months prior to entry: myocardial&#xD;
             infarction, severe / unstable angina, coronary artery / peripheral artery bypass&#xD;
             surgery, symptomatic congestive heart failure, or cerebrovascular accidents&#xD;
&#xD;
          -  positive Human Immunodeficiency Virus (HIV) antibody&#xD;
&#xD;
          -  Currently participating in other clinical trials&#xD;
&#xD;
          -  Pregnant or lactating women or have fertility without taking contraception&#xD;
&#xD;
          -  Suffering from other serious acute and chronic physical or mental problems, or&#xD;
             abnormal laboratory tests, will increase the risk of participation or drug use, or&#xD;
             interfere with the judgment of the findings, judged by the researchers as participate&#xD;
             in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiren Yu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Weili Yang, Doctor</last_name>
    <phone>+8613989879196</phone>
    <email>yangweili@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiren Yu</last_name>
    <phone>+8657187236147</phone>
    <email>yujr0909@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiren Yu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Zhejiang University</investigator_affiliation>
    <investigator_full_name>Yu jiren</investigator_full_name>
    <investigator_title>Chief of Gastrointestinal Surgery</investigator_title>
  </responsible_party>
  <keyword>Progression-free survival</keyword>
  <keyword>Gastrointestinal Stromal Tumors</keyword>
  <keyword>neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

